Workflow
APELOA(000739)
icon
Search documents
11月19日增减持汇总:龙利得等3股增持 人民同泰等17股减持(表)
Xin Lang Zheng Quan· 2025-11-19 14:05
Group 1: Company Buybacks - Longlide plans to repurchase company shares for no less than 56 million yuan [2] - Hanshuo Technology has obtained a commitment letter for a stock repurchase loan from a financial institution [2] - Prolo Pharmaceutical intends to use between 180 million to 360 million yuan to buy back company shares [2] Group 2: Company Sell-offs - Suda Co., Ltd. plans to reduce its holdings by no more than 3% [2] - Hunan Baiyin intends to reduce its holdings by no more than 1.95% [2] - Zimi Co., Ltd. plans to reduce its holdings by no more than 1% [2] - Zhongshui Fishery's third-largest shareholder has reduced its holdings by 2.5888 million shares, bringing its stake down to 5% [2] - We Online's investors plan to collectively reduce their holdings by no more than 5.94% [2] - Renmin Tongtai's controlling shareholder plans to reduce its holdings by no more than 1% [2] - Yanshiwei's fourth and fifth largest shareholders plan to reduce their holdings by no more than 1.5% and 1% respectively [2] - Langke Intelligent's shareholders plan to reduce their holdings by no more than 1.68% [2] - Yingben Co., Ltd.'s director plans to reduce his holdings by no more than 0.03% [2] - Sunshine Power has completed the implementation of share reduction plans by some directors and senior management [2] - Dipu Technology's shareholder plans to reduce his holdings by no more than 1.55% [2] - MediWest's shareholder plans to reduce his holdings by no more than 1.64% [2] - Huahai Qingke's shareholder plans to reduce his holdings by no more than 1% [2] - Liyuan Technology's shareholder plans to reduce his holdings by no more than 2.0303% [2] - New Emerging Equipment's shareholders plan to collectively reduce their holdings by no more than 3.13% [2] - Jinqiao Information's director plans to reduce his holdings by no more than 0.0675% [2] - Kanglongda's shareholder plans to reduce his holdings by no more than 3% [2]
11月19日晚间公告 | 合富中国停牌核查结束;德赛西威发布面向机器人领域的AI计算终端
Xuan Gu Bao· 2025-11-19 11:58
Mergers and Acquisitions - Chenyi Intelligent plans to acquire 55% of Huaze Electronics through cash payment [1] - Beijiete's wholly-owned subsidiary intends to acquire 55% of Dahao Mining for 225 million yuan [1] Share Buybacks and Equity Transfers - Chenzhan Optoelectronics' controlling shareholder is transferring 5.02% of shares [2] - Huamin Co., Ltd. plans to transfer 5.17% of shares by Jianxianghuihong [2] - Pro Pharmaceutical intends to repurchase shares worth between 180 million to 360 million yuan, with a maximum price of 23 yuan per share [2] - Ganyue Expressway's actual controller will change from the Provincial Department of Transportation to the Provincial State-owned Assets Supervision and Administration Commission [2] External Investments and Daily Operations - Hefei China has completed its suspension review and resumed trading [3] - Dwei Co., Ltd. is advancing the procedures for lithium battery new energy projects in Hunan Chenzhou [4] - Desay SV plans to launch an AI computing terminal for the robotics sector [4] - Neusoft Group received a notification from a major domestic automotive manufacturer to supply intelligent cockpit domain controllers, with a total expected supply amount of 4.2 billion yuan [4] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision, acquiring 60% ownership post-investment [5] - Dongfang Electric intends to invest 910 million yuan to hold 49% in a joint venture [6] - Bailian Group's subsidiary plans to transfer 100% of its stake in Yangpu Century Bailian for 78.286 million yuan [6] - Ruisheng Intelligent's subsidiary won a bid for a China Mobile ICT project, focusing on computing server hardware and systems [6] - Zhifei Biological's clinical trial application for the ZFA01 adjuvant vaccine has been accepted [7] - Haizheng Pharmaceutical's subsidiary is collaborating with East China Institute on a biomanufacturing project for heparin [8] - Baiyang Pharmaceutical's Zap Therapeutic plans to invest 4.9 million USD in Baiyang Sap to expedite the clinical introduction of the ZAP-X Mars surgical robot [8] - Jinbei Automotive plans to invest 5.8 billion yuan and purchase equity in Changchun Zhongtuo Molding Technology [9] - Baili Tianheng has secured a commitment from Bank of China Sichuan Branch for a total of no less than 8 billion yuan in comprehensive credit support [10]
11月19日晚间重要公告一览
Xi Niu Cai Jing· 2025-11-19 10:32
Group 1 - Kanglongda's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 4.83 million shares [1] - The company specializes in the research, production, and sales of special and ordinary labor protection gloves [1] Group 2 - Haizheng Pharmaceutical's subsidiary plans to collaborate with East China Institute on a biological method for synthesizing heparin, with a project contract amount not exceeding 120 million yuan [2] - The company focuses on the research, production, and sales of chemical raw materials and formulations [3] Group 3 - Tianyin Holdings received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [4] - The company is engaged in the sales of smart terminals, e-commerce, lottery, mobile resale, and mobile internet businesses [4] Group 4 - Shanghai Yashi plans to use up to 200 million yuan of temporarily idle raised funds for cash management in high-security, liquid deposit products [5] - The company specializes in supply chain logistics and execution trade [6] Group 5 - Parker New Materials intends to use 130 million yuan of idle raised funds to purchase structured deposits with expected annual yields between 0.59% and 2.9001% [7] - The company focuses on the research, production, and sales of various types of ring forgings, free forgings, and die forgings [7] Group 6 - Huayang New Materials appointed Jing Hongsheng as the new general manager [8] Group 7 - Liyuan Technology's shareholder plans to reduce holdings by up to 2.03% of the company's shares, totaling no more than 3.04 million shares [9] - The company specializes in the research, design, and integration of environmental water treatment systems and hydrogen fuel cell engine systems [9] Group 8 - Shengnuo Biopharmaceutical's subsidiary received approval for the listing application of Visepegenatide raw materials, a GLP-1 receptor agonist for treating type 2 diabetes and obesity [10][11] - The company focuses on the research, production, and sales of peptide raw materials and formulations [10] Group 9 - Puluo Pharmaceutical plans to repurchase shares worth between 180 million and 360 million yuan, with a maximum price of 23 yuan per share [12] - The company specializes in the research, production, and sales of raw material intermediates and innovative drugs [12] Group 10 - Dongfang Electric's subsidiary plans to establish a joint venture with Anhui Waneng Energy, with a registered capital of approximately 1.857 billion yuan [13] - The company is involved in the development, design, manufacturing, and sales of advanced power generation equipment [13] Group 11 - Hefei China announced that its stock will resume trading on November 20 after completing a review of abnormal trading fluctuations [14] - The company focuses on international trade and after-sales services related to in vitro diagnostic medical devices [14] Group 12 - Dafeng Industrial won a bid for the stage equipment project of the Shenzhen International Performing Arts Center, with a contract amount of 165 million yuan [15] - The company specializes in cultural sports equipment, digital art technology, and operation services [15] Group 13 - Baiyunshan's subsidiary received a drug registration certificate for An Gong Niu Huang Wan in Vietnam [16] - The company is engaged in the research, manufacturing, and sales of traditional Chinese and Western medicines [16] Group 14 - Neusoft Group received a notification to supply intelligent cockpit domain controllers for multiple models from a well-known domestic automobile manufacturer, with an estimated total amount of about 4.2 billion yuan [17] - The company focuses on providing industry solutions and software products [17] Group 15 - Huayu Pharmaceutical's product received overseas marketing approval [18] - The company specializes in the research, production, and sales of innovative and high-quality generic drugs in the oncology field [18] Group 16 - Yao Pi Glass received approval from the CSRC for its stock issuance to specific investors [19] - The company specializes in the production and sales of float glass and processed glass [19] Group 17 - Guangyu Yuan's vice president Wang Junbo resigned due to work adjustments [20] - The company focuses on the production and sales of traditional Chinese medicine products [20] Group 18 - Biyi Co. received approval from the CSRC for its stock issuance to specific investors [21] - The company specializes in the design, manufacturing, and sales of smart small household appliances [21] Group 19 - Sunshine Nuohe's application for acquiring 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. through share issuance and convertible bonds has been accepted by the Shanghai Stock Exchange [22] - The company provides comprehensive drug research and development services for domestic pharmaceutical enterprises and research institutions [22] Group 20 - Longxin General plans to increase capital in its wholly-owned subsidiary by no more than 1.65 billion yuan [23] - The company specializes in the research, production, and sales of motorcycles and engines [23] Group 21 - Jiekang Equipment received a corrective order from the Tianjin Securities Regulatory Bureau due to internal control deficiencies [24] - The company specializes in the research, production, and sales of nuclear biochemical safety equipment [24] Group 22 - Wantong Technology plans to raise no more than 920 million yuan through a private placement to supplement working capital [25] - The company focuses on information technology services for highways and ports [25] Group 23 - Dongshan Precision has submitted an application for H-share listing to the Hong Kong Stock Exchange [26] - The company specializes in the research, production, and sales of electronic circuit products and precision components [26] Group 24 - Yonghe Intelligent Control plans to publicly transfer 100% equity of its wholly-owned subsidiary Kunming Medical Oncology Hospital [27] - The company specializes in water and heating valve fittings, tumor precision radiation therapy, and photovoltaic battery businesses [27] Group 25 - Aok Shares signed a strategic cooperation framework agreement with Suzhou Qitian New Materials Co., Ltd. [28] - The company focuses on the research and production of high-end new materials derived from ethylene oxide and ethylene [28] Group 26 - Hongquan Technology's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 299,440 shares [29] - The company specializes in the research, production, and sales of intelligent connected products and software platform development [29] Group 27 - Shilong Industrial's controlling shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 7.2 million shares [30] - The company specializes in the research, production, and sales of chemical products [30] Group 28 - Tangrenshen decided to terminate the investment in the "Dongchong Phase III Pig Breeding Base Construction Project," reallocating the remaining funds of 78.9587 million yuan to supplement working capital [31] - The company specializes in the research, production, and sales of feed, pigs, meat products, and animal health products [31] Group 29 - Gaode Infrared's actual controller plans to reduce holdings by up to 3% of the company's shares, totaling no more than 12.8 million shares [32] - The company specializes in infrared focal plane detector chips and infrared thermal imaging systems [32] Group 30 - Kangyuan Pharmaceutical's actual controller recently increased holdings by 20,000 shares [33] - The company specializes in the research, production, and sales of pharmaceuticals [33] Group 31 - Haida Group plans to repurchase shares worth between 1 billion and 1.6 billion yuan, with a maximum price of 62.00 yuan per share [34] - The company provides overall solutions for animal husbandry [34] Group 32 - Qizhong Technology's 850 million yuan convertible bonds have been approved for listing [35] - The company specializes in advanced packaging and testing of integrated circuits [35] Group 33 - Dingyang Technology launched the new SNA5000B series vector network analyzer [36] - The company specializes in the research, production, and sales of general electronic testing and measuring instruments [36] Group 34 - Airo Energy plans to distribute a cash dividend of 0.9375 yuan per share to all shareholders [37] - The company specializes in photovoltaic energy storage systems and products [37] Group 35 - Hechuan Technology's actual controller and some directors plan to reduce holdings by up to 6% of the company's shares [38] - The company specializes in the research, production, and sales of industrial automation products [38] Group 36 - China First Heavy Industries' chairman was arrested for suspected bribery [39] - The company specializes in heavy machinery manufacturing for various industries [39] Group 37 - Lianhuan Pharmaceutical plans to invest 15 million yuan in joint research with Nanjing University for anti-thrombotic small nucleic acid drugs [40] - The company specializes in the manufacturing and sales of chemical raw materials [40] Group 38 - Anxu Biotech's shareholder plans to reduce holdings by up to 0.94% of the company's shares, totaling no more than 120,000 shares [41] - The company specializes in the research, production, and sales of POCT reagents and instruments [41] Group 39 - Yaxiang Integration's shareholder reduced holdings by 130,000 shares [42] - The company specializes in providing cleanroom engineering and related services for high-tech electronic industries [42] Group 40 - Zhongwen Media plans to use up to 9.5 billion yuan of idle funds to purchase financial products [43] - The company specializes in traditional publishing and various new media businesses [43]
普洛药业(000739.SZ):拟回购1.8亿元-3.6亿元公司股份
Ge Long Hui A P P· 2025-11-19 09:20
格隆汇11月19日丨普洛药业(000739.SZ)公布,拟回购资金总额不低于人民币18,000万元且不超过人民币 36,000万元公司股份,回购股份价格不超过人民币23元/股,本次回购股份用于股权激励或员工持股计 划。 ...
普洛药业(000739.SZ)拟斥资1.8亿元至3.6亿元实施回购
智通财经网· 2025-11-19 08:53
普洛药业(000739.SZ)披露025年第二次回购公司股份方案,公司回购股份拟用于股权激励或员工持股计 划,本次回购资金总额不低于人民币1.8亿元(含)且不超过人民币3.6亿元(含)。本次回购股份价格不超过 人民币23元/股(含)。回购期限自公司董事会审议通过本次回购股份方案之日起12个月内。 ...
普洛药业:拟回购不低于1.8亿元且不超过3.6亿元公司股份
Sou Hu Cai Jing· 2025-11-19 08:48
(记者 曾健辉) 免责声明:本文内容与数据仅供参考,不构成投资建议,使用前请核实。据此操作,风险自担。 每日经济新闻 每经AI快讯,普洛药业(SZ 000739,收盘价:15.29元)11月19日晚间发布公告称,普洛药业股份有限 公司拟使用自有资金及金融机构回购贷款通过深圳证券交易所交易系统以集中竞价交易方式回购公司股 份,主要内容如下。本次回购股份拟用于股权激励或员工持股计划。本次回购资金总额不低于人民币 1.8亿元(含)且不超过人民币3.6亿元(含)。本次回购股份价格不超过人民币23元/股(含),未超过 公司董事会通过回购股份决议前三十个交易日公司股票交易均价的150%。回购期限自公司董事会审议 通过本次回购股份方案之日起12个月内。 2025年1至6月份,普洛药业的营业收入构成为:医药行业占比99.6%,其他业务占比0.4%。 截至发稿,普洛药业市值为177亿元。 每经头条(nbdtoutiao)——炒股亏了保险兜底,月收益高达100%?"安我股保"宣称推出全网首款炒股 保险,两大机构连忙撇清关系 ...
普洛药业(000739) - 关于2025年第二次回购公司股份方案的公告
2025-11-19 08:47
证券代码:000739 证券简称:普洛药业 公告编号:2025-67 普洛药业股份有限公司 (4)回购期限:自公司董事会审议通过本次回购股份方案之日起 12 个月内。 (5)回购资金来源:自有资金及金融机构回购贷款。(截至本公告披露日, 中国农业银行股份有限公司东阳市支行已向公司出具了《中国农业银行贷款承诺 函》,同意向公司提供不超过 32,400 万元人民币的股票回购贷款。) 公司实际贷款金额不超过本次回购方案金额的上限,且具体业务满足《中国 人民银行、金融监管总局、中国证监会关于设立股票回购增持再贷款有关事宜的 通知》等要求,并符合银行按照相关规定制定的贷款政策、标准和程序。 2.截至本公告披露日,公司持股 5%以上股东无减持计划。 关于 2025 年第二次回购公司股份方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示: 1. 普洛药业股份有限公司(以下简称"公司")拟使用自有资金及金融机 构回购贷款通过深圳证券交易所交易系统以集中竞价交易方式回购公司股份,主 要内容如下: (1)回购股份的用途:本次回购股份拟用于股权激励或员工持股计 ...
普洛药业拟斥资1.8亿元至3.6亿元实施回购
Zhi Tong Cai Jing· 2025-11-19 08:46
普洛药业(000739)(000739.SZ)披露025年第二次回购公司股份方案,公司回购股份拟用于股权激励或 员工持股计划,本次回购资金总额不低于人民币1.8亿元(含)且不超过人民币3.6亿元(含)。本次回购股份 价格不超过人民币23元/股(含)。回购期限自公司董事会审议通过本次回购股份方案之日起12个月内。 ...
普洛药业(000739) - 第九届董事会第十七次会议决议公告
2025-11-19 08:45
证券代码:000739 证券简称:普洛药业 公告编号:2025-66 普洛药业股份有限公司 第九届董事会第十七次会议决议公告 2025 年 11 月 20 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司(以下简称"公司")第九届董事会第十七次会议通 知于2025年11月8日以短信及电子邮件等方式发出。会议于2025年11月18日在公 司一楼会议室以现场会议的方式召开,本次会议由董事长祝方猛先生主持。会议 应出席董事9名,实际出席董事9名,公司部分高管列席了本次会议。本次会议的 召开符合《公司法》和《公司章程》的有关规定。经与会董事审议表决,通过如 下决议: 一、《关于 2025 年第二次回购公司股份方案的议案》 公司拟使用自有资金及金融机构回购贷款通过深圳证券交易所交易系统以 集中竞价交易方式回购公司股份,本次回购股份拟用于股权激励或员工持股计划。 本次回购股份价格不超过人民币 23 元/股,回购资金总额:不低于人民币 18,000 万元(含)且不超过人民币 36,000 万元(含)。在回购价格不超过人民币 23 元/股的条件下,按回 ...
普洛药业:拟使用1.8亿元-3.6亿元回购公司股份
Mei Ri Jing Ji Xin Wen· 2025-11-19 08:45
每经AI快讯,11月19日,普洛药业(000739.SZ)公告称,公司拟使用自有资金及金融机构回购贷款通过 深圳证券交易所交易系统以集中竞价交易方式回购公司股份,回购股份价格不超过人民币23元/股,回 购资金总额为不低于人民币1.8亿元(含)且不超过人民币3.6亿元(含)。预计可回购股份数量为783万 股—1,565万股,约占公司总股本的0.68%—1.35%。回购期限为自董事会审议通过回购股份方案之日起 12个月内。若公司在股份回购完成后36个月内未能实施前述用途,未使用部分将依法履行相关程序后予 以注销。 ...